<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70402">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01776541</url>
  </required_header>
  <id_info>
    <org_study_id>V89_04</org_study_id>
    <nct_id>NCT01776541</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults</brief_title>
  <official_title>A Phase II, Randomized, Observer-Blind,Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Thailand: Food and Drug Administration</authority>
    <authority>Australia: Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived
      influenza vaccine in adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>To select a vaccine dose based on the achievement of CBER criteria for further development</measure>
    <time_frame>Day 43 (3 weeks after second vaccination)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroprotection and Seroconversion rate measured  3 weeks after second dose of vaccine administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with solicited local and systemic adverse events</measure>
    <time_frame>7 days post vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with unsolicited adverse events</measure>
    <time_frame>3 weeks post vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with serious adverse events, medically attended adverse events, adverse events  leading to withdrawal and adverse events of special interest</measure>
    <time_frame>Day 1 through Day 732</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of CHMP criteria 3 weeks after after second dose of vaccine administration</measure>
    <time_frame>Day 43</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroprotection, Seroconversion rate and GMRs measured  3 weeks after second dose of vaccine administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of CBER and CHMP criteria 3 weeks after first dose of vaccine administration</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroprotection, Seroconversion rate and GMRs measured  3 weeks after first dose of vaccine administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of CBER and CHMP criteria 3 weeks after booster dose of vaccine administration</measure>
    <time_frame>Day 387</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroprotection, Seroconversion rate and GMRs measured  3 weeks after booster dose of vaccine administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">978</enrollment>
  <condition>Pandemic H5N1 Influenza</condition>
  <arm_group>
    <arm_group_label>aH5N1c-High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>aH5N1c-Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted  H5N1 pandemic influenza vaccine</intervention_name>
    <description>Comparison of two doses of aH5N1c vaccine</description>
    <arm_group_label>aH5N1c-High Dose</arm_group_label>
    <arm_group_label>aH5N1c-Low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult subjects 18 to 64 years of age,

          2. Individuals willing to provide written informed consent,

          3. Individuals in good health,

          4. Individuals willing to allow for their serum samples to be stored beyond the study
             period.

        Exclusion Criteria:

          1. Individuals not able to understand and follow study procedures,

          2. History of any significant illness,

          3. History of any chronic medical condition or progressive disease,

          4. Presence of medically significant cancer,

          5. Known or suspected impairment/alteration of immune function,

          6. Presence of any progressive or severe neurologic disorder,

          7. Presence of any bleeding disorders or conditions that prolongs bleeding time,

          8. History of allergy to vaccine components,

          9. Receipt of any other investigational product within 30 days prior to entry into the
             study,

         10. History of previous H5N1 vaccination,

         11. Receipt of any other type of seasonal vaccination within 2 months prior to entry into
             the study,

         12. Receipt of any other vaccine within 2 weeks prior to entry into the study

         13. Body temperature ≥38°C.0 (≥100.4° F) and/or acute illness within 3 days of intended
             study vaccination,

         14. Pregnant or breast feeding,

         15. Females of childbearing potential refusing to use acceptable method of birth control,

         16. Body mass index (BMI) ≥ 35 kg/m2,

         17. History of drug or alcohol abuse,

         18. Any planned surgery during study period,

         19. Individuals conducting the study and their immediate family members,

         20. Individuals with behavioral or cognitive impairment or psychiatric diseases.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1 Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2 Mercy Health Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3 Saint Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4 Benchmark Medical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>48 Hunter Clinical Research</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2292</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>46 CMAX</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>47 Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>80 Faculty of Tropical Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>1040</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 3, 2013</lastchanged_date>
  <firstreceived_date>January 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza, Pandemic, H5N1, Adults</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza in Birds</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
